ReviewPlanta2026
The CRISPR-dCas9 epigenetic toolbox: prospects for modulating gene expression in climate-resilient crops.
Review in Planta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MAIN
conclusionCRISPR-dCas9 epigenome editing represents a paradigm shift from static DNA sequence editing to dynamic reprogramming of gene expression, offering a powerful and precise toolbox with the potential to develop stable and climate-resilient crops without altering DNA sequences. The escalating challenges of global food security, driven by climate change and population growth, necessitate innovative crop improvement strategies that extend beyond conventional breeding. Although CRISPR-Cas9 has revolutionized plant biotechnology through direct genome editing, CRISPR-based epigenome editing has emerged as a new frontier. By repurposing nuclease-dead Cas9 as a programmable targeting platform fused to epigenetic effector domains, researchers can precisely modulate gene expression without altering the DNA sequence. This approach has already yielded compelling successes, such as the engineering of durable resistance to cassava bacterial blight through targeted epigenetic silencing of a susceptibility gene. This review focuses primarily on the current state of CRISPR-based epigenome editing systems, including acetyltransferases, demethylases, DNA methyltransferases, and deacetylases, and their applications in crop improvement research. We critically evaluate their mechanisms in rewriting epigenetic regulatory information, their demonstrated efficacy in enhancing yield components, disease resistance, and abiotic stress tolerance, and their potential to create stable meiotically heritable epialleles, although most demonstrations remain at the proof-of-concept stage in model plants, with field validation in major crops still limited. This review provides a balanced analysis of key challenges, including editing specificity, context-dependency, delivery limitations, and regulatory considerations. Finally, we outline future directions focusing on technological refinement, multi-omics integration, and field validation. Epigenome editing shows promise as a conceptually distinct and transformative approach in crop biotechnology, through targeted modulation of a plant's epigenetic landscape. However, its full potential hinges on overcoming challenges related to stability, predictability, and field-scale validation.
Indexed as
Identifiers
42888353What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.